The Antimicrobial Effect of Fluorides (Acidulated Phosphate, Sodium and Stannous) on Actinomyces viscosus

1979 ◽  
Vol 58 (8) ◽  
pp. 1824-1829 ◽  
Author(s):  
Nancy A. Yoon ◽  
Charles W. Berry

The effect of three commercially prepared fluoride compounds (acidulated phosphate fluoride 1.23% F-, stannous fluoride 0.4%, and sodium fluoride 0.05%) diluted to various concentrations with brain heart infusion broth, on the growth of five strains of Actinomyces viscosus following 1 and 24 hours' exposure to the fluorides was studied. Results demonstrated that SnF2 was the most effective growth inhibitor of the organisms at 500 ppm F- after 1 hour and at 100 ppm F-after 24 hours' exposure. APF and NaF were not effective within a 1 hour exposure period, but did suppress growth of the organisms at 200 ppm in the cultures exposed for 24 hours.

1980 ◽  
Vol 43 (1) ◽  
pp. 4-6 ◽  
Author(s):  
M. AYAZ ◽  
L. O. LUEDECKE ◽  
A. L. BRANEN

The antimicrobial effect of butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) on three enterotoxigenic strains of Staphylococcus aureus in Brain Heart Infusion broth (BHI) was evaluated by turbidity measurements. Also, the interaction of these compounds with pH and NaCl on growth of S. aureus strain 100 was measured. Inhibition of S. aureus growth increased with an increase in the concentration of BHA and/or BHT. Complete inhibition of S. aureus growth occurred in BHI with 1.12 μmole of BHA/ml or 0.70 μmole of BHT/ml as well as with a combination of 0.25 μmole of both BHT and BHA/ml. Inhibition of S. aureus growth by BHA or BHT was substantial at pH 7.0 and with 2% NaCl. When 0.84 μmole or greater of BHA/ml and 0.47 μmole or greater of BHT/ml were added to BHL, growth of S. aureus 100 was inhibited to the extent that enterotoxin A could not be detected after 24 h of incubation.


1965 ◽  
Vol 11 (5) ◽  
pp. 823-827 ◽  
Author(s):  
R. Pakula ◽  
A. H. W. Hauschild

The competence-provoking factor produced by the highly transformable group H streptococcus, strain Challis, was used to provoke efficient transformability in the poorly transformable group H streptococcus, strain Wicky. Transformations to streptomycin resistance were carried out with C14-labelled DNA which was extracted from bacteria fed with thymidine-2-C14.When cultures of strain Wicky were grown in Difco brain–heart infusion broth, supplemented with serum, and treated with competence factor and deoxyribonucleic acid, 25 to 40% of viable units were transformed while no transformation occurred without the factor. At the same time, the incorporation of C14 into cells treated with competence factor was higher than incorporation of C14 into untreated cells.Crude preparations of the competence factor had a retarding effect on growth of the streptococcus, irrespective of whether DNA was added.


1957 ◽  
Vol 36 (1) ◽  
pp. 118-123 ◽  
Author(s):  
Robert H. Walsh ◽  
William H. Nebergall ◽  
Joseph C. Muhler ◽  
Harry G. Day

1990 ◽  
Vol 53 (9) ◽  
pp. 790-792 ◽  
Author(s):  
M. W. GRIFFITHS

Using a reversed passive latex agglutination assay, about 85% of psychrotrophic Bacillus spp. tested were shown to produce diarrhoegenic toxin during growth on brain heart infusion broth at 25°C. The majority of these strains were identified as Bacillus cereus or cereus-related strains. However, a number of other species was capable of synthesizing the toxin. Further investigation of four psychrotrophic Bacilli showed that the toxin was produced during growth in milk at temperatures ranging from 6 to 21°C. Toxin production increased with increasing temperatures and was not synthesized in appreciable quantities until the bacterial count exceeded 1 × 107 cfu/ml.


2010 ◽  
Vol 73 (3) ◽  
pp. 552-555 ◽  
Author(s):  
J. D. STOPFORTH ◽  
D. VISSER ◽  
R. ZUMBRINK ◽  
L. van DIJK ◽  
E. W. BONTENBAL

Ready-to-eat (RTE) meat products have been identified as a significant source of listeriosis in humans in the United States. Meat processors in the United States are required to use one of three alternatives to control L. monocytogenes in RTE meats: (i) a postlethality inactivation treatment along with a L. monocytogenes growth inhibitor; (ii) a postlethality inactivation treatment or a growth inhibitor; or (iii) sanitation measures and intensive testing. Lauric arginate (LAE) has been proposed as an effective postlethality inactivation treatment. The present study was conducted to investigate the antimicrobial effect of a lactate-diacetate blend in the formulation combined with surface application of LAE on cooked cured ham inoculated with L. monocytogenes, vacuum packaged, and stored at 4°C for up to 90 days. The treatments evaluated were (i) control ham with no added antimicrobials (control); (ii) ham formulated with 1.68% potassium lactate and 0.12% sodium diacetate (PLSD); (iii) control ham with 0.07% LAE as a surface treatment (LAE); and (iv) ham formulated with PLSD and LAE surface treatment (sprayed in bag and distributed across meat surface during vacuum packing) (PLSD+LAE). Use of only LAE as a surface treatment resulted in an initial 1-log CFU/g reduction in levels of L. monocytogenes on ham; however, this reduction only delayed the growth of the pathogen to 8 log CFU/g by 12 days when compared with the control ham without added antimicrobials. Use of PLSD in the formulation of ham resulted in a complete inhibition of L. monocytogenes throughout storage. The combination of PLSD in the formulation and a surface treatment with LAE resulted in an initial 0.7-log CFU/g reduction of the pathogen on ham and complete inhibition of the pathogen at the reduced level throughout storage. Formulation of ham with a lactate-diacetate blend combined with lauric arginate as a surface treatment will allow RTE meat processors to effectively achieve alternative 1 status, as designated by the U.S. Department of Agriculture Food Safety and Inspection Service, in their facilities.


2005 ◽  
Vol 68 (3) ◽  
pp. 597-601 ◽  
Author(s):  
NANCY G. FAITH ◽  
MARK L. TAMPLIN ◽  
DARRELL BAYLES ◽  
JOHN B. LUCHANSKY ◽  
CHARLES J. CZUPRYNSKI

Several outbreaks of listeriosis have been associated with contamination of wieners and other ready-to-eat meat products. In this study, we addressed the question of whether emulsification in, or growth on, wieners triggers a response in the listerial cells that makes them more virulent or protects them against the harsh environment of the gastrointestinal tract in mice. Our results indicate that Listeria monocytogenes Scott A grows poorly, if at all, in one brand of commercially prepared wieners inoculated with 5 × 103 to 5 × 106 CFU per package and incubated at 15°C. Neither L. monocytogenes Scott A emulsified in a slurry of homogenized wieners nor recovered from wiener package fluid after a 7-day incubation at 15°C were more virulent when inoculated into the stomachs of A/J mice than L. monocytogenes Scott A grown in brain heart infusion broth. These findings suggest that the ability of L. monocytogenes Scott A to cause systemic infection following introduction into the gastrointestinal tract was not improved by incubation with wieners or suspension in a meat matrix.


Author(s):  
Gabrielle S. Dijksteel ◽  
Magda M. W. Ulrich ◽  
Marcel Vlig ◽  
Peter H. Nibbering ◽  
Robert A. Cordfunke ◽  
...  

Abstract Background We investigated the efficacy of a synthetic antimicrobial peptide SAAP-148, which was shown to be effective against Methicillin-resistant Staphylococcus aureus (MRSA) on tape-stripped mice skin. Unexpectedly, SAAP-148 was not effective against MRSA in our pilot study using rats with excision wounds. Therefore, we investigated factors that might have contributed to the poor efficacy of SAAP-148. Subsequently, we optimised the protocol and assessed the efficacy of SAAP-148 in an adapted rat study. Methods We incubated 100 µL of SAAP-148 with 1 cm2 of a wound dressing for 1 h and determined the unabsorbed volume of peptide solution. Furthermore, 105 colony forming units (CFU)/mL MRSA were exposed to increasing dosages of SAAP-148 in 50% (v/v) human plasma, eschar- or skin extract or PBS. After 30 min incubation, the number of viable bacteria was determined. Next, ex vivo skin models were inoculated with MRSA for 1 h and exposed to SAAP-148. Finally, excision wounds on the back of rats were inoculated with 107 CFU MRSA overnight and treated with SAAP-148 for 4 h or 24 h. Subsequently, the number of viable bacteria was determined. Results Contrary to Cuticell, Parafilm and Tegaderm film, < 20% of peptide solution was recovered after incubation with gauze, Mepilex border and Opsite Post-op. Furthermore, in plasma, eschar- or skin extract > 20-fold higher dosages of SAAP-148 were required to achieve a 2-log reduction (LR) of MRSA versus SAAP-148 in PBS. Exposure of ex vivo models to SAAP-148 for 24 h resulted in a 4-fold lower LR than a 1 h or 4 h exposure period. Additionally, SAAP-148 caused a 1.3-fold lower mean LR at a load of 107 CFU compared to 105 CFU MRSA. Moreover, exposure of ex vivo excision wound models to SAAP-148 resulted in a 1.5-fold lower LR than for tape-stripped skin. Finally, SAAP-148 failed to reduce the bacterial counts in an adapted rat study. Conclusions Several factors, such as absorption of SAAP-148 by wound dressings, components within wound exudates, re-colonisation during the exposure of SAAP-148, and a high bacterial load may contribute to the poor antimicrobial effect of SAAP-148 against MRSA in the rat model.


1958 ◽  
Vol 37 (4) ◽  
pp. 638-648 ◽  
Author(s):  
John A. Gray ◽  
Henry C. Schweizer ◽  
Francis B. Rosevear ◽  
Robert W. Broge

Sign in / Sign up

Export Citation Format

Share Document